Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 30 January 2012 | By Alexander Gaffney, RAC
Pakistan is facing calls from industry for a drug regulatory authority to be formed after a batch of cardiac drugs given to patients at a government-run hospital has been linked to more than 100 deaths.
Patients at the Punjab Institute of Cardiology were given one or more drugs manufactured by relatively small, local companies. The drugs, given to roughly 40,000 patients, generated side effects that were initially confused with dengue fever. Almost 250 patients remain hospitalized as a result of the drugs, and the owners of the manufacturing companies responsible for making the drugs remain under arrest pending an investigation and the return of lab results.
As a result of the deaths and injuries, a Pakistani industry consortium known as Pharma Bureau is calling for the formation of an independent drug regulatory authority. According to Pakistan Today, Pharma Bureau cited the need to regain public confidence in the pharmaceutical industry after the scandal. They further noted that many companies are skirting the existing regulations entirely, while those that attempt to get their drugs and molecules through the official registration process are often subjected to a slow and arduous process.
According to the BBC, the pharmaceuticals market in Pakistan is "intensely competitive" and the calls for an independent drug regulatory authority may be partially in response to this competition.
Tags: Cardiology, Punjab, Deaths, Pakistan, Pharmaceuticals, Scandal, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.